| Name | Title | Contact Details |
|---|
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, apitegromab (SRK-015), a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA. We are currently evaluating apitegromab in our TOPAZ Phase 2 proof-of-concept trial in patients with later-onset (Type 2 and Type 3) SMA. Positive six-month interim analysis results were announced in October 2020 and top-line data for the full 12-month treatment period are anticipated in the second quarter of 2021. In addition, we are conducting our DRAGON Phase 1 proof-of-concept trial for SRK-181, a highly specific inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors. We believe SRK-181 has the potential to overcome resistance and meaningfully increase the number of patients who may benefit from checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies. Utilizing our proprietary platform, we are creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.
Transave is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marlon Ramos at Frange Blue-Hairstylist is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world`s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
CBCC has treated over 75,000 patients since we first opened. We have continually expanded and have earned the recognition as the largest free standing, privately held cancer center in the nation. While our motivation has always been to offer the finest care available, our story starts in a small office in 1984. Dr. Ravi Patel opened a 1200 square foot cancer clinic as a way to bring his vision of providing cancer patients with specialized medical and emotional care to Bakersfield. In the years since, CBCC has changed in many ways, but the purpose has always remained the same—we believe you shouldn`t have to travel the state for state-of-the-art cancer care.